BRAF and melanoma: Whilst known recurrent activating mutations were identified in BRAF and NRAS, a high number of inactivating mutations were identified in NF1. Notably, almost half (26/56) of BRAF and NRAS wild-type melanomas had an NF1 mutation, most identified by loss of heterozygosity (LOH).